Copyright Reports & Markets. All rights reserved.

Global Cellular Tumor Antigen p53 Market Professional Survey Report 2019

Request for Sample of this report
Buy now

Table of Contents

    Executive Summary

      1 Industry Overview of Cellular Tumor Antigen p53

      • 1.1 Definition of Cellular Tumor Antigen p53
      • 1.2 Cellular Tumor Antigen p53 Segment by Type
        • 1.2.1 Global Cellular Tumor Antigen p53 Production Growth Rate Comparison by Types (2014-2025)
        • 1.2.2 COTI-2
        • 1.2.3 D-12PGJ3
        • 1.2.4 APR-246
        • 1.2.5 ATRN-502
        • 1.2.6 Cenersen Sodium
        • 1.2.7 MJ-05
        • 1.2.8 MX-225
        • 1.2.9 Others
      • 1.3 Cellular Tumor Antigen p53 Segment by Applications
        • 1.3.1 Global Cellular Tumor Antigen p53 Consumption Comparison by Applications (2014-2025)
        • 1.3.2 Ovarian Cancer
        • 1.3.3 Prostate Cancer
        • 1.3.4 Brain Cancer
        • 1.3.5 Others
      • 1.4 Global Cellular Tumor Antigen p53 Overall Market
        • 1.4.1 Global Cellular Tumor Antigen p53 Revenue (2014-2025)
        • 1.4.2 Global Cellular Tumor Antigen p53 Production (2014-2025)
        • 1.4.3 North America Cellular Tumor Antigen p53 Status and Prospect (2014-2025)
        • 1.4.4 Europe Cellular Tumor Antigen p53 Status and Prospect (2014-2025)
        • 1.4.5 China Cellular Tumor Antigen p53 Status and Prospect (2014-2025)
        • 1.4.6 Japan Cellular Tumor Antigen p53 Status and Prospect (2014-2025)
        • 1.4.7 Southeast Asia Cellular Tumor Antigen p53 Status and Prospect (2014-2025)
        • 1.4.8 India Cellular Tumor Antigen p53 Status and Prospect (2014-2025)

      2 Manufacturing Cost Structure Analysis

      • 2.1 Raw Material and Suppliers
      • 2.2 Manufacturing Cost Structure Analysis of Cellular Tumor Antigen p53
      • 2.3 Manufacturing Process Analysis of Cellular Tumor Antigen p53
      • 2.4 Industry Chain Structure of Cellular Tumor Antigen p53

      3 Development and Manufacturing Plants Analysis of Cellular Tumor Antigen p53

      • 3.1 Capacity and Commercial Production Date
      • 3.2 Global Cellular Tumor Antigen p53 Manufacturing Plants Distribution
      • 3.3 Major Manufacturers Technology Source and Market Position of Cellular Tumor Antigen p53
      • 3.4 Recent Development and Expansion Plans

      4 Key Figures of Major Manufacturers

      • 4.1 Cellular Tumor Antigen p53 Production and Capacity Analysis
      • 4.2 Cellular Tumor Antigen p53 Revenue Analysis
      • 4.3 Cellular Tumor Antigen p53 Price Analysis
      • 4.4 Market Concentration Degree

      5 Cellular Tumor Antigen p53 Regional Market Analysis

      • 5.1 Cellular Tumor Antigen p53 Production by Regions
        • 5.1.1 Global Cellular Tumor Antigen p53 Production by Regions
        • 5.1.2 Global Cellular Tumor Antigen p53 Revenue by Regions
      • 5.2 Cellular Tumor Antigen p53 Consumption by Regions
      • 5.3 North America Cellular Tumor Antigen p53 Market Analysis
        • 5.3.1 North America Cellular Tumor Antigen p53 Production
        • 5.3.2 North America Cellular Tumor Antigen p53 Revenue
        • 5.3.3 Key Manufacturers in North America
        • 5.3.4 North America Cellular Tumor Antigen p53 Import and Export
      • 5.4 Europe Cellular Tumor Antigen p53 Market Analysis
        • 5.4.1 Europe Cellular Tumor Antigen p53 Production
        • 5.4.2 Europe Cellular Tumor Antigen p53 Revenue
        • 5.4.3 Key Manufacturers in Europe
        • 5.4.4 Europe Cellular Tumor Antigen p53 Import and Export
      • 5.5 China Cellular Tumor Antigen p53 Market Analysis
        • 5.5.1 China Cellular Tumor Antigen p53 Production
        • 5.5.2 China Cellular Tumor Antigen p53 Revenue
        • 5.5.3 Key Manufacturers in China
        • 5.5.4 China Cellular Tumor Antigen p53 Import and Export
      • 5.6 Japan Cellular Tumor Antigen p53 Market Analysis
        • 5.6.1 Japan Cellular Tumor Antigen p53 Production
        • 5.6.2 Japan Cellular Tumor Antigen p53 Revenue
        • 5.6.3 Key Manufacturers in Japan
        • 5.6.4 Japan Cellular Tumor Antigen p53 Import and Export
      • 5.7 Southeast Asia Cellular Tumor Antigen p53 Market Analysis
        • 5.7.1 Southeast Asia Cellular Tumor Antigen p53 Production
        • 5.7.2 Southeast Asia Cellular Tumor Antigen p53 Revenue
        • 5.7.3 Key Manufacturers in Southeast Asia
        • 5.7.4 Southeast Asia Cellular Tumor Antigen p53 Import and Export
      • 5.8 India Cellular Tumor Antigen p53 Market Analysis
        • 5.8.1 India Cellular Tumor Antigen p53 Production
        • 5.8.2 India Cellular Tumor Antigen p53 Revenue
        • 5.8.3 Key Manufacturers in India
        • 5.8.4 India Cellular Tumor Antigen p53 Import and Export

      6 Cellular Tumor Antigen p53 Segment Market Analysis (by Type)

      • 6.1 Global Cellular Tumor Antigen p53 Production by Type
      • 6.2 Global Cellular Tumor Antigen p53 Revenue by Type
      • 6.3 Cellular Tumor Antigen p53 Price by Type

      7 Cellular Tumor Antigen p53 Segment Market Analysis (by Application)

      • 7.1 Global Cellular Tumor Antigen p53 Consumption by Application
      • 7.2 Global Cellular Tumor Antigen p53 Consumption Market Share by Application (2014-2019)

      8 Cellular Tumor Antigen p53 Major Manufacturers Analysis

      • 8.1 Advaxis, Inc.
        • 8.1.1 Advaxis, Inc. Cellular Tumor Antigen p53 Production Sites and Area Served
        • 8.1.2 Advaxis, Inc. Product Introduction, Application and Specification
        • 8.1.3 Advaxis, Inc. Cellular Tumor Antigen p53 Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.1.4 Main Business and Markets Served
      • 8.2 American Gene Technologies International Inc.
        • 8.2.1 American Gene Technologies International Inc. Cellular Tumor Antigen p53 Production Sites and Area Served
        • 8.2.2 American Gene Technologies International Inc. Product Introduction, Application and Specification
        • 8.2.3 American Gene Technologies International Inc. Cellular Tumor Antigen p53 Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.2.4 Main Business and Markets Served
      • 8.3 Aprea AB
        • 8.3.1 Aprea AB Cellular Tumor Antigen p53 Production Sites and Area Served
        • 8.3.2 Aprea AB Product Introduction, Application and Specification
        • 8.3.3 Aprea AB Cellular Tumor Antigen p53 Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.3.4 Main Business and Markets Served
      • 8.4 Cellceutix Corporation
        • 8.4.1 Cellceutix Corporation Cellular Tumor Antigen p53 Production Sites and Area Served
        • 8.4.2 Cellceutix Corporation Product Introduction, Application and Specification
        • 8.4.3 Cellceutix Corporation Cellular Tumor Antigen p53 Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.4.4 Main Business and Markets Served
      • 8.5 Critical Outcome Technologies Inc.
        • 8.5.1 Critical Outcome Technologies Inc. Cellular Tumor Antigen p53 Production Sites and Area Served
        • 8.5.2 Critical Outcome Technologies Inc. Product Introduction, Application and Specification
        • 8.5.3 Critical Outcome Technologies Inc. Cellular Tumor Antigen p53 Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.5.4 Main Business and Markets Served
      • 8.6 Eleos Inc.
        • 8.6.1 Eleos Inc. Cellular Tumor Antigen p53 Production Sites and Area Served
        • 8.6.2 Eleos Inc. Product Introduction, Application and Specification
        • 8.6.3 Eleos Inc. Cellular Tumor Antigen p53 Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.6.4 Main Business and Markets Served
      • 8.7 ORCA Therapeutics B.V.
        • 8.7.1 ORCA Therapeutics B.V. Cellular Tumor Antigen p53 Production Sites and Area Served
        • 8.7.2 ORCA Therapeutics B.V. Product Introduction, Application and Specification
        • 8.7.3 ORCA Therapeutics B.V. Cellular Tumor Antigen p53 Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.7.4 Main Business and Markets Served
      • 8.8 OSE Pharma SA
        • 8.8.1 OSE Pharma SA Cellular Tumor Antigen p53 Production Sites and Area Served
        • 8.8.2 OSE Pharma SA Product Introduction, Application and Specification
        • 8.8.3 OSE Pharma SA Cellular Tumor Antigen p53 Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.8.4 Main Business and Markets Served
      • 8.9 PCI Biotech Holding ASA
        • 8.9.1 PCI Biotech Holding ASA Cellular Tumor Antigen p53 Production Sites and Area Served
        • 8.9.2 PCI Biotech Holding ASA Product Introduction, Application and Specification
        • 8.9.3 PCI Biotech Holding ASA Cellular Tumor Antigen p53 Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.9.4 Main Business and Markets Served
      • 8.10 Quark Pharmaceuticals, Inc.
        • 8.10.1 Quark Pharmaceuticals, Inc. Cellular Tumor Antigen p53 Production Sites and Area Served
        • 8.10.2 Quark Pharmaceuticals, Inc. Product Introduction, Application and Specification
        • 8.10.3 Quark Pharmaceuticals, Inc. Cellular Tumor Antigen p53 Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.10.4 Main Business and Markets Served
      • 8.11 Stemline Therapeutics, Inc.
      • 8.12 Shenzen SiBiono GeneTech Co., Ltd.
      • 8.13 SK Biopharmaceuticals Co., Ltd.
      • 8.14 Tara Immuno-Oncology Therapeutics LLC
      • 8.15 Z53 Therapeutics, LLC

      9 Development Trend of Analysis of Cellular Tumor Antigen p53 Market

      • 9.1 Global Cellular Tumor Antigen p53 Market Trend Analysis
        • 9.1.1 Global Cellular Tumor Antigen p53 Market Size (Volume and Value) Forecast 2019-2025
      • 9.2 Cellular Tumor Antigen p53 Regional Market Trend
        • 9.2.1 North America Cellular Tumor Antigen p53 Forecast 2019-2025
        • 9.2.2 Europe Cellular Tumor Antigen p53 Forecast 2019-2025
        • 9.2.3 China Cellular Tumor Antigen p53 Forecast 2019-2025
        • 9.2.4 Japan Cellular Tumor Antigen p53 Forecast 2019-2025
        • 9.2.5 Southeast Asia Cellular Tumor Antigen p53 Forecast 2019-2025
        • 9.2.6 India Cellular Tumor Antigen p53 Forecast 2019-2025
      • 9.3 Cellular Tumor Antigen p53 Market Trend (Product Type)
      • 9.4 Cellular Tumor Antigen p53 Market Trend (Application)
      • 10.1 Marketing Channel
        • 10.1.1 Direct Marketing
        • 10.1.2 Indirect Marketing
      • 10.3 Cellular Tumor Antigen p53 Customers

      11 Market Dynamics

      • 11.1 Market Trends
      • 11.2 Opportunities
      • 11.3 Market Drivers
      • 11.4 Challenges
      • 11.5 Influence Factors

      12 Conclusion

        13 Appendix

        • 13.1 Methodology/Research Approach
          • 13.1.1 Research Programs/Design
          • 13.1.2 Market Size Estimation
          • 13.1.3 Market Breakdown and Data Triangulation
        • 13.2 Data Source
          • 13.2.1 Secondary Sources
          • 13.2.2 Primary Sources
        • 13.3 Author List

        The global Cellular Tumor Antigen p53 market was valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025.
        This report focuses on Cellular Tumor Antigen p53 volume and value at global level, regional level and company level. From a global perspective, this report represents overall Cellular Tumor Antigen p53 market size by analyzing historical data and future prospect.
        Regionally, this report categorizes the production, apparent consumption, export and import of Cellular Tumor Antigen p53 in North America, Europe, China, Japan, Southeast Asia and India.
        For each manufacturer covered, this report analyzes their Cellular Tumor Antigen p53 manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.

        The following manufacturers are covered:
        Advaxis, Inc.
        American Gene Technologies International Inc.
        Aprea AB
        Cellceutix Corporation
        Critical Outcome Technologies Inc.
        Eleos Inc.
        ORCA Therapeutics B.V.
        OSE Pharma SA
        PCI Biotech Holding ASA
        Quark Pharmaceuticals, Inc.
        Stemline Therapeutics, Inc.
        Shenzen SiBiono GeneTech Co., Ltd.
        SK Biopharmaceuticals Co., Ltd.
        Tara Immuno-Oncology Therapeutics LLC
        Z53 Therapeutics, LLC

        Segment by Regions
        North America
        Europe
        China
        Japan
        Southeast Asia
        India

        Segment by Type
        COTI-2
        D-12PGJ3
        APR-246
        ATRN-502
        Cenersen Sodium
        MJ-05
        MX-225
        Others

        Segment by Application
        Ovarian Cancer
        Prostate Cancer
        Brain Cancer
        Others

        Buy now